In today's episode of Just the Facts...
Imugene has hit a key milestone with Precision BioSciences, triggering a US$3 million payment and new shares as it gears up for FDA talks on a pivotal trial of its allogeneic CAR T therapy, azer-cel.
FireFly Metals has appointed former Rio Tinto executive Leanne Heywood as an independent director — bringing strong copper marketing experience as the company advances its Green Bay copper-gold project.
Alkane Resources has struck more high-grade gold at its Tomingley operations in NSW — including hits of up to 22.8 grams per tonne — expanding resources at McLeans and Roswell for future underground growth.
Anteris has secured FDA approval to begin its global PARADIGM trial of the DurAVR heart valve in severe aortic stenosis — a major step toward U.S. approval for its next-generation transcatheter valve.
#ASXNews #Biotech #Copper #GoldMining #ClinicalTrials #HealthcareStocks #MiningNews #StockMarketAustralia